D. E. Shaw & Co., Inc. Precision Biosciences Inc Transaction History

D. E. Shaw & Co., Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.34 - $0.69 $95,091 - $192,980	-279,682 Reduced 64.35%	154,954 $52,000
Q2 2023 Aug 14, 2023	SELL	$0.52 - $0.91 $19,233 - $33,658	-36,987 Reduced 7.84%	434,636 $230,000
Q1 2023 May 15, 2023	BUY	$0.7 - $1.41 $3,494 - $7,038	4,992 Added 1.07%	471,623 $353,000
Q4 2022 Feb 14, 2023	SELL	$0.97 - $45.0 $50,691 - $2.35 Million	-52,259 Reduced 10.07%	466,631 $555,000
Q3 2022 Nov 14, 2022	BUY	$1.22 - $40.8 $310,548 - $10.4 Million	254,548 Added 96.29%	518,890 $674,000
Q2 2022 Aug 15, 2022	BUY	$1.15 - $3.34 $303,993 - $882,902	264,342 New	264,342 $423,000
Q4 2020 Feb 16, 2021	SELL	$5.98 - $12.47 $128,659 - $268,292	-21,515 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$4.65 - $8.73 $100,044 - $187,825	21,515 New	21,515 $133,000
Q4 2019 Feb 14, 2020	SELL	$6.32 - $19.66 $83,025 - $258,273	-13,137 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$8.03 - $14.82 $105,490 - $194,690	13,137 New	13,137 $110,000

2.56M

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $531M
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.